Indiana University Research And Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10705949.5Aexternal-prioritypatent/EP2395990B1/en
Application filed by Indiana University Research And Technology CorporationfiledCriticalIndiana University Research And Technology Corporation
Publication of CY1116642T1publicationCriticalpatent/CY1116642T1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Άτομα που έχουν διαγνωστεί είτε με συν-νοσηρό ή ιδιοπαθή αυτισμό θεραπεύονται με acamprosate. Οι ασθενείς γενικά εμφάνισαν αξιοσημείωτη βελτίωση σε πρωτεύοντα αποτελέσματα όπως εκτιμώνται χρησιμοποιώντας, για παράδειγμα, τυπικά κλινικά μέτρα για την λειτουργικότητα που περιλαμβάνει τις Κλινικές Συνολικές Εντυπώσεις Βελτίωσης (CGI-I) και τις κλίμακες Συνολικών Κλινικών Εντυπώσεων Σοβαρότητας (CGI-S).People diagnosed with either co-morbid or idiopathic autism are treated with acamprosate. Patients generally showed significant improvement in primary outcomes as assessed using, for example, standard clinical measures of functionality including the Clinical Overall Improvement Impressions (CGI-I) and the SG-Scales.
CY20151100134T2009-02-122015-02-11
MATERIALS AND METHODS FOR TREATMENT OF DEVELOPMENTAL DISORDERS THAT INCLUDE DISEASE AND SPECIAL AUTISM
CY1116642T1
(en)